- Everyman’s Rosehill snaps up 900,000 shares
- Staffline director buys 2,000,000 shares
- AstraZeneca chair bets on new obesity and diabetes drugs
Michael Rosehill, non-executive director of premium cinema group Everyman (EMAN:AIM) has bought 300,000 shares for 57p for the total value of £171,000 and 500,000 shares at 56p for a total value of £280,000 on 22 November.
Rosehill has also bought a further 100,000 shares at 56p for a total value of £56,000 on 22 November.
The move comes as no surprise as Rosehill has been buying Everyman shares throughout the year through private equity group Blue Coast, where he is also a director.
Shares in Everyman are down 26% year-to-date to the 61p mark, Rosehill might be viewing this purchase as a bargain?
Rosehill now owns 21,803,639 shares in the company equating to 23.9% of the company’s issued capital.
STAFFLIINE DIRECTOR SNAPS UP 2,000,000 SHARES
A person closely associated with Thomas Spain, a non-executive director and interim chairman of Nottingham-based Staffline (STAF:AIM), one of the biggest recruiters in the UK, has snapped up 2,000,000 shares at 24p for a total value of £472,000 on 21 November.
As a result of the transaction, Henry Spain Services Limited has a notifiable interest of 33,548,700 shares.
Staffline saw its pre-tax losses widen for the six months ending 30 June, posting a loss of £4.3 million, up from £1 million in the same year ago period.
However, the company said that full year trading is in line with market expectations.
Staffline shares have been down 35% year-to-date.
ASTRAZENECA CHAIR BUYS OVER £200,000 SHARES
Michel Demare, non-executive director and chair of the board of AstraZeneca (AZN) has bought 1,000 shares at £101.05 for a total value of £101,052 and 1,000 shares for £101.70 for the total value of £101,70 on the 21 and 22 November respectively.
Demare’s move could be seen as an optimistic one as the pharmaceutical giant recently reported upbeat third quarter results with strong sales from its cancer franchise.
Total revenue rose 5% to $11 billion despite a $2.8 billion fall in Covid-10 product sales.
The company’s foray into obesity and diabetes drugs could be a strong future bet.
The pharmaceutical giant’s shares however are down 12% year-to-date.